<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kuo IY</submitter><funding>NIDDK NIH HHS</funding><funding>NIH HHS</funding><pagination>e0153632</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4833351</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(4)</volume><pubmed_abstract>Mutations in the gene for polycystin 2 (Pkd2) lead to polycystic kidney disease, however the main cause of mortality in humans is cardiac related. We previously showed that 5 month old Pkd2+/- mice have altered calcium-contractile activity in cardiomyocytes, but have preserved cardiac function. Here, we examined 1 and 9 month old Pkd2+/- mice to determine if decreased amounts of functional polycystin 2 leads to impaired cardiac function with aging. We observed changes in calcium handling proteins in 1 month old Pkd2+/- mice, and these changes were exacerbated in 9 month old Pkd2+/- mice. Anatomically, the 9 month old Pkd2+/- mice had thinner left ventricular walls, consistent with dilated cardiomyopathy, and the left ventricular ejection fraction was decreased. Intriguingly, in response to acute isoproterenol stimulation to examine ?-adrenergic responses, the 9 month old Pkd2+/- mice exhibited a stronger contractile response, which also coincided with preserved localization of the ?2 adrenergic receptor. Importantly, the Pkd2+/- mice did not have any renal impairment. We conclude that the cardiac-related impact of decreased polycystin 2 progresses over time towards cardiac dysfunction and altered adrenergic signaling. These results provide further evidence that polycystin 2 provides a critical function in the heart, independent of renal involvement.</pubmed_abstract><journal>PloS one</journal><pubmed_title>Decreased Polycystin 2 Levels Result in Non-Renal Cardiac Dysfunction with Aging.</pubmed_title><pmcid>PMC4833351</pmcid><funding_grant_id>5P30DK034989</funding_grant_id><funding_grant_id>K99DK101585</funding_grant_id><funding_grant_id>S10 OD020142</funding_grant_id><funding_grant_id>OD020142</funding_grant_id><funding_grant_id>P01 DK057751</funding_grant_id><funding_grant_id>P30 DK090744</funding_grant_id><funding_grant_id>P30DK090744</funding_grant_id><funding_grant_id>K99 DK101585</funding_grant_id><funding_grant_id>5P01DK057751</funding_grant_id><funding_grant_id>P30 DK034989</funding_grant_id><pubmed_authors>Duong SL</pubmed_authors><pubmed_authors>Kuo IY</pubmed_authors><pubmed_authors>Ehrlich BE</pubmed_authors><pubmed_authors>Nguyen L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Decreased Polycystin 2 Levels Result in Non-Renal Cardiac Dysfunction with Aging.</name><description>Mutations in the gene for polycystin 2 (Pkd2) lead to polycystic kidney disease, however the main cause of mortality in humans is cardiac related. We previously showed that 5 month old Pkd2+/- mice have altered calcium-contractile activity in cardiomyocytes, but have preserved cardiac function. Here, we examined 1 and 9 month old Pkd2+/- mice to determine if decreased amounts of functional polycystin 2 leads to impaired cardiac function with aging. We observed changes in calcium handling proteins in 1 month old Pkd2+/- mice, and these changes were exacerbated in 9 month old Pkd2+/- mice. Anatomically, the 9 month old Pkd2+/- mice had thinner left ventricular walls, consistent with dilated cardiomyopathy, and the left ventricular ejection fraction was decreased. Intriguingly, in response to acute isoproterenol stimulation to examine ?-adrenergic responses, the 9 month old Pkd2+/- mice exhibited a stronger contractile response, which also coincided with preserved localization of the ?2 adrenergic receptor. Importantly, the Pkd2+/- mice did not have any renal impairment. We conclude that the cardiac-related impact of decreased polycystin 2 progresses over time towards cardiac dysfunction and altered adrenergic signaling. These results provide further evidence that polycystin 2 provides a critical function in the heart, independent of renal involvement.</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016</publication><modification>2021-02-21T02:06:55Z</modification><creation>2019-03-26T22:53:49Z</creation></dates><accession>S-EPMC4833351</accession><cross_references><pubmed>27081851</pubmed><doi>10.1371/journal.pone.0153632</doi></cross_references></HashMap>